21.18

2.29% 0.475

Pre-market: 21.59 0.415 +1.96%

Roivant Sciences Ltd (ROIV)

Overview News Price History Option Chain Financials Why ROIV Down? Discussions Forecast

Roivant Sciences Ltd stock is traded at $21.18, with a volume of 4.65M. It is up +2.29% in the last 24 hours and up +6.57% over the past month. Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Previous Close:

$20.70

Open:

$20.7

24h Volume:

4.65M

Relative Volume:

0.56

Market Cap:

$14.73B

Revenue:

$125.68M

Net Income/Loss:

$4.81B

P/E Ratio:

3.7478

EPS:

5.65

Net Cash Flow:

$-781.21M

1W Performance:

+1.46%

1M Performance:

+6.57%

6M Performance:

+88.89%

1Y Performance:

+74.86%

1-Day Range:

$20.53

$21.33

1-Week Range:

$19.96

$21.33

52-Week Range:

$8.73

$21.35

Roivant Sciences Ltd Stock (ROIV) Company Profile

Name

Roivant Sciences Ltd

Sector

Healthcare (1131)

Industry

Biotechnology (632)

Phone

441-295-5950

Address

7TH FLOOR, 50 BROADWAY, LONDON

Employee

750

Twitter

Next Earnings Date

2025-02-10

Latest SEC Filings

ROIV's Discussions on Twitter

Compare ROIV with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ROIV Roivant Sciences Ltd	21.18	14.40B	125.68M	4.81B	-781.21M	5.65
VRTX Vertex Pharmaceuticals Inc	457.26	117.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	722.83	76.06B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	464.56	62.53B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	916.31	56.75B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.04	44.10B	447.02M	-1.18B	-906.14M	-6.1812

Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-02-25	Initiated	Citigroup	Buy
Jul-10-25	Resumed	Goldman	Buy
Feb-15-24	Initiated	Wolfe Research	Outperform
Jan-05-24	Initiated	Piper Sandler	Overweight
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-17-23	Initiated	Guggenheim	Buy
Jun-08-23	Initiated	BofA Securities	Neutral
Oct-27-22	Initiated	JP Morgan	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight
Dec-15-21	Initiated	Goldman	Buy
Nov-08-21	Initiated	H.C. Wainwright	Buy
Oct-28-21	Initiated	Citigroup	Buy
Oct-26-21	Initiated	Cowen	Outperform
Oct-26-21	Initiated	Jefferies	Buy
Oct-26-21	Initiated	Truist	Buy

View All

Roivant Sciences Ltd Stock (ROIV) Latest News

Dec 04, 2025

Why Roivant Sciences Ltd. stock could rally in 2025Dividend Hike & Weekly Breakout Watchlists - Newser

Dec 04, 2025

How Roivant Sciences Ltd. (87S) stock compares with market leadersJuly 2025 Trends & Community Verified Trade Signals - Newser

Dec 04, 2025

Is Roivant Sciences Ltd. (87S) stock undervalued by metricsWeekly Trend Recap & High Conviction Buy Zone Alerts - Newser

Dec 04, 2025

Will Roivant Sciences Ltd. stock recover faster than peers2025 Market Overview & Capital Efficiency Focused Strategies - Newser

Dec 04, 2025

How Roivant Sciences Ltd. (87S) stock trades after rate cutsM&A Rumor & High Win Rate Trade Tips - Newser

Dec 04, 2025

Is Roivant Sciences Ltd. (87S) stock safe for risk averse investors2025 Stock Rankings & Growth Oriented Trading Recommendations - Newser

Dec 04, 2025

Is Roivant Sciences Ltd. stock safe for conservative investorsEarnings Miss & Weekly High Conviction Trade Ideas - Newser

Dec 04, 2025

Dec 03, 2025